BioVersys Expands Collaboration with GSK and Boosts Series C Funding by CHF 12.3 Million
Overview
BioVersys AG, a clinical-stage biopharmaceutical company, and GSK plc (LSE/NYSE: GSK), a global biopharma leader, have announced an expansion of their strategic collaboration to accelerate the clinical development of alpibectir (BVL-GSK098) for tuberculosis (TB) treatment.
Alpibectir
- Alpibectir, a novel small molecule developed through a successful public-private partnership involving GSK, Pasteur Institute Lille, and the University of Lille, is currently undergoing evaluation in a Phase 2a proof-of-concept study in pulmonary TB patients in South Africa.
- This compound, in combination with ethionamide (Eto), introduces a fresh approach to overcoming resistance and enhancing the effectiveness of existing antibiotics.
Extension in Collaboration
- The collaboration between GSK and BioVersys will extend beyond the current Phase 2a study to develop alpibectir for both pulmonary TB and TB meningitis programs, aiming to make the treatment available to patients expeditiously.
- Investment:- In addition to their collaboration, GSK will make an equity investment in BioVersys’ latest funding round, enhancing the Series C financing by CHF 12.3 million, totaling proceeds of CHF 44.9 million for the Series C round to date. These funds will support the clinical development of BioVersys’ portfolio, including BV100, a potential breakthrough antibiotic targeting Acinetobacter baumannii.
BioVersys on The Collab
- • BioVersys, expressed enthusiasm about the expanded collaboration with GSK and the progress in alpibectir's development.
- • He emphasized the urgency in addressing TB, a global health threat with inadequate treatment options.
GSK on Potential of Alpibectir
GSK, highlighted the commitment to combatting TB and the potential of alpibectir to diversify treatment options. He emphasized the importance of partnerships in addressing global health challenges effectively.
About TB
- TB, caused by Mycobacterium tuberculosis, remains a significant global health concern, with millions of new cases and deaths annually, and a rising incidence of drug-resistant strains.
- The collaboration between BioVersys and GSK represents a concerted effort to address this pressing public health issue.
